BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2018

  • ID: 4461739
  • Drug Pipelines
  • 116 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co Ltd
  • Handok Inc
  • Loxo Oncology Inc
  • Otonomy Inc
  • MORE
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'BDNFNT 3 Growth Factors Receptor - Pipeline Review, H1 2018'; BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 20 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation.

The report 'BDNFNT 3 Growth Factors Receptor - Pipeline Review, H1 2018' outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 2, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Cardiovascular, Ear Nose Throat Disorders, Genetic Disorders, Metabolic Disorders and Ophthalmology which include indications Alzheimer's Disease, Solid Tumor, Non-Small Cell Lung Cancer, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Neuroendocrine Tumors, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Brain Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Fibrosarcoma, Gastrointestinal Stromal Tumor (GIST), Huntington Disease, Metastatic Colorectal Cancer, Multiple Sclerosis, Neuroblastoma, Ovarian Cancer, Parkinson's Disease, Renal Cell Carcinoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Thyroid Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Biliary Tumor, Bladder Cancer, Carcinoid Tumor, Charcot-Marie-Tooth Disease, Diabetic Retinopathy, Endometrial Cancer, Epilepsy, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatocellular Carcinoma, Ischemic Optic Neuropathy, Major Depressive Disorder, Melanoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neurology, Non-Rhabdomyosarcoma, Non-Small Cell Lung Carcinoma, Ocular Melanoma, Osteosarcoma, Papillary Thyroid Cancer, Peritoneal Cancer, Pheochromocytoma, Pontine Glioma, Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rett Syndrome, Rhabdomyosarcoma, Stroke, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
  • The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics
Reasons to Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co Ltd
  • Handok Inc
  • Loxo Oncology Inc
  • Otonomy Inc
  • MORE
Introduction

Report Coverage

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Overview

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

AstraZeneca Plc

Boehringer Ingelheim GmbH

Chronos Therapeutics Ltd

Daiichi Sankyo Co Ltd

Exelixis Inc

Handok Inc

Ignyta Inc

Loxo Oncology Inc

MimeTech Srl

Otonomy Inc

Plexxikon Inc

Takeda Pharmaceutical Co Ltd

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Drug Profiles

ACD-855 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Agonize TrKB for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-7451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNN-27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-6051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larotrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-22A4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-22B10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTO-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-0131304 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize TrkA and TrkB for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize TRKB for Neurodegenrative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize TrkB for CNS Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Dormant Products

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Discontinued Products

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jan 16, 2018: Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma

Jan 15, 2018: Data To Be Presented On cabozantinib (Cabometyx) At 2018 ASCO Gastrointestinal Symposium

Jan 15, 2018: Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX

Jan 09, 2018: Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Jan 04, 2018: Exelixis Announces Amendment to Clinical Research Protocol for Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

Dec 20, 2017: Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers

Dec 20, 2017: Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers

Dec 19, 2017: Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma

Dec 07, 2017: Bayer to Highlight New Oncology Research on larotrectinib at ASH 2017

Dec 04, 2017: Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers

Nov 21, 2017: Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium

Oct 19, 2017: AlzeCure to Present Data on NeuroRestore Project at 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD)

Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset

Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors

Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Addex Therapeutics Ltd, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Boehringer Ingelheim GmbH, H1 2018

Pipeline by Chronos Therapeutics Ltd, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Pipeline by Exelixis Inc, H1 2018

Pipeline by Handok Inc, H1 2018

Pipeline by Ignyta Inc, H1 2018

Pipeline by Loxo Oncology Inc, H1 2018

Pipeline by MimeTech Srl, H1 2018

Pipeline by Otonomy Inc, H1 2018

Pipeline by Plexxikon Inc, H1 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Chronos Therapeutics Ltd
  • Daiichi Sankyo Co Ltd
  • Exelixis Inc
  • Handok Inc
  • Ignyta Inc
  • Loxo Oncology Inc
  • MimeTech Srl
  • Otonomy Inc
  • Plexxikon Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll